AQNEURSA
GrowthNDAORALFOR SUSPENSIONPriority Review
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
5/8 — Partial
Priority Review
AQNEURSA by IntraBio is a-t is unknown. Approved for neurological manifestations of niemann-pick disease type c (npc) in adults, ataxia in adults. First approved in 2024.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AQNEURSA is an oral suspension approved September 2024 for neurological manifestations of Niemann-Pick disease type C (NPC) and ataxia in adults. The mechanism of action is unknown, limiting clarity on its pharmacologic class and differentiation. It represents an NDA-approved small molecule addressing rare neurological disorders with limited treatment options.
Growth10.5 years to LOE
Recent approval in growth phase signals expanding team needs; rare disease designation suggests niche commercial model with specialized field and medical affairs focus.
Mechanism of Action
A-T is unknown.
Worked on AQNEURSA at IntraBio? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.